KBY Biotech Indexv0.0.34
Search
← Pipeline|MAY-IIT-189

MAY-IIT-189

Approved
By Mayo Clinic
Source: Trial-derived·Trials: 1
Modality
mAb
MOA
CD47i
Target
TNFα
Pathway
JAK/STAT
Thymoma
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
~Mar 2018
→ ~Jun 2019
Phase 3
~Sep 2019
→ ~Dec 2020
NDA/BLA
~Mar 2021
→ ~Jun 2022
Approved
Sep 2022
→ Jan 2027
ApprovedCurrent
NCT08734627
1,295 pts·Thymoma
2022-09→2027-01·Terminated
1,295 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-01-129mo awayPh3 Readout· Thymoma
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
Approved
Termina…
Catalysts
Ph3 Readout
2027-01-12 · 9mo away
Thymoma
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT08734627ApprovedThymomaTerminated12956MWD
Competitors (10)
DrugCompanyPhaseTargetMOA
NirarelsinJohnson & JohnsonPhase 2PRMT5CD47i
CevizanubrutinibJohnson & JohnsonPreclinicalFcRnCD47i
CeviglumideRocheNDA/BLAB7-H3CD47i
NVS-1475NovartisPhase 2MeninCD47i
ABB-3951AbbViePhase 2/3TNFαCDK2i
AZN-6294AstraZenecaPhase 2/3APOC3CD47i
ZenonesiranGSKPreclinicalDLL3CD47i
AMG-7379AmgenPreclinicalDLL3CD47i
GIL-6239Gilead SciencesPhase 2TNFαCGRPant
MRN-8225ModernaPreclinicalTNFαSGLT2i